- Home
- PMEC vs TPST Comparison
PMEC vs TPST Comparison
Compare PMEC & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMEC
- TPST
- Stock Information
- Founded
- PMEC 1984
- TPST 2011
- Country
- PMEC Singapore
- TPST United States
- Employees
- PMEC N/A
- TPST N/A
- Industry
- PMEC
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- PMEC
- TPST Health Care
- Exchange
- PMEC Nasdaq
- TPST Nasdaq
- Market Cap
- PMEC 29.3M
- TPST 27.2M
- IPO Year
- PMEC 2023
- TPST N/A
- Fundamental
- Price
- PMEC $0.76
- TPST $0.97
- Analyst Decision
- PMEC
- TPST Strong Buy
- Analyst Count
- PMEC 0
- TPST 4
- Target Price
- PMEC N/A
- TPST $20.00
- AVG Volume (30 Days)
- PMEC 57.5K
- TPST 3.3M
- Earning Date
- PMEC 12-26-2024
- TPST 11-12-2024
- Dividend Yield
- PMEC N/A
- TPST N/A
- EPS Growth
- PMEC N/A
- TPST N/A
- EPS
- PMEC N/A
- TPST N/A
- Revenue
- PMEC $72,524,000.00
- TPST N/A
- Revenue This Year
- PMEC N/A
- TPST N/A
- Revenue Next Year
- PMEC N/A
- TPST N/A
- P/E Ratio
- PMEC N/A
- TPST N/A
- Revenue Growth
- PMEC 5.07
- TPST N/A
- 52 Week Low
- PMEC $0.49
- TPST $0.86
- 52 Week High
- PMEC $4.15
- TPST $6.00
- Technical
- Relative Strength Index (RSI)
- PMEC 50.46
- TPST 42.46
- Support Level
- PMEC $0.67
- TPST $0.94
- Resistance Level
- PMEC $0.78
- TPST $1.16
- Average True Range (ATR)
- PMEC 0.06
- TPST 0.09
- MACD
- PMEC -0.00
- TPST 0.01
- Stochastic Oscillator
- PMEC 52.14
- TPST 39.34
About PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.